Improving the success rate and reducing the time that it takes to bring a new drug to the market represent important challenges for both academia and the pharmaceutical industry. High-throughput genomic analysis of cancer may assist streamlining this process through providing clinically relevant response markers, suggesting rational combination treatment strategies for biologically targeted agents and defining the next generation of therapeutic targets.